

# CITATION REPORT

List of articles citing

**Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity**

**DOI: 10.1038/bmt.2015.307**

**Bone Marrow Transplantation, 2016, 51, 479-91.**

**Source:** <https://exaly.com/paper-pdf/65654078/citation-report.pdf>

**Version:** 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
68	Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?. <i>OncoTargets and Therapy</i> , <b>2016</b> , 9, 4843-58	4.4	4
67	Predictors of survival in patients with surgical spine multiple myeloma metastases. <i>Surgical Oncology</i> , <b>2016</b> , 25, 178-83	2.5	8
66	The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective. <i>Advances in Therapy</i> , <b>2016</b> , 33, 1896-1920	4.1	11
65	Management of relapsed and refractory multiple myeloma in modern times: Incorporating new agents into decision-making. <i>American Journal of Hematology</i> , <b>2016</b> , 91, 1044-51	7.1	6
64	Ex Vivo Oncolytic Virotherapy with Myxoma Virus Arms Multiple Allogeneic Bone Marrow Transplant Leukocytes to Enhance Graft versus Tumor. <i>Molecular Therapy - Oncolytics</i> , <b>2017</b> , 4, 31-40	6.4	21
63	Moving Beyond Maximum Tolerated Dose for Targeted Oncology Drugs: Use of Clinical Utility Index to Optimize Venetoclax Dosage in Multiple Myeloma Patients. <i>Clinical Pharmacology and Therapeutics</i> , <b>2017</b> , 102, 970-976	6.1	18
62	Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , <b>2017</b> , 178, 571-582	4.5	39
61	Optimizing current and emerging therapies in multiple myeloma: a guide for the hematologist. <i>Therapeutic Advances in Hematology</i> , <b>2017</b> , 8, 55-70	5.7	25
60	Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , <b>2017</b> , 18, 1327-1337	21.7	248
59	Chimeric antigen receptor T-cell therapies for multiple myeloma. <i>Blood</i> , <b>2017</b> , 130, 2594-2602	2.2	128
58	Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma. <i>Leukemia</i> , <b>2017</b> , 31, 2695-2701	10.7	25
57	High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting. <i>BMC Cancer</i> , <b>2017</b> , 17, 151	4.8	15
56	The Challenges of Daratumumab in Transfusion Medicine. <i>Laboratory Medicine</i> , <b>2017</b> , 48, 6-9	1.6	9
55	Effect of pomalidomide on relapsed/refractory multiple myeloma: a systematic review and meta-analysis. <i>Journal of Cancer</i> , <b>2017</b> , 8, 1801-1808	4.5	4
54	Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2018</b> , 18, 335-345	2	57
53	Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , <b>2018</b> , 59, 2588-2594	1.9	16
52	Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials. <i>Hematological Oncology</i> , <b>2018</b> , 36, 463-470	1.3	9

51	A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma. <i>Critical Reviews in Oncology/Hematology</i> , <b>2018</b> , 121, 74-89	7	15
50	Safety and efficacy of haploidentical stem cell transplantation for multiple myeloma. <i>Bone Marrow Transplantation</i> , <b>2018</b> , 53, 507-510	4.4	4
49	Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma. <i>Bone Marrow Transplantation</i> , <b>2018</b> , 53, 701-707	4.4	14
48	Durable treatment response of relapsing CNS plasmacytoma using intrathecal chemotherapy, radiotherapy, and Daratumumab. <i>Clinical Case Reports (discontinued)</i> , <b>2018</b> , 6, 723-728	0.7	14
47	Evaluation of Cardiovascular Toxicity Associated with Treatments Containing Proteasome Inhibitors in Multiple Myeloma Therapy. <i>High Blood Pressure and Cardiovascular Prevention</i> , <b>2018</b> , 25, 209-218	2.9	14
46	A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center. <i>Leukemia and Lymphoma</i> , <b>2018</b> , 59, 515-518 <sup>1.9</sup>	1.9	3
45	Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 728-734	2.2	164
44	Cardiovascular adverse events in multiple myeloma patients. <i>Journal of Thoracic Disease</i> , <b>2018</b> , 10, S4296-S4305 <sup>2</sup>	5.4	2
43	Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 1811-1822	59.2	268
42	Treatment of relapsed refractory multiple myeloma: which new PI-based combination treatments do patients prefer?. <i>Patient Preference and Adherence</i> , <b>2018</b> , 12, 2387-2396	2.4	10
41	Bacteraemia post-autologous haematopoietic stem cell transplantation in the absence of antibacterial prophylaxis: a decade's experience from Lebanon. <i>Infection</i> , <b>2018</b> , 46, 823-835	5.8	1
40	Spinal metastases in multiple myeloma: A high-risk subgroup for ISS III patients. <i>Surgical Oncology</i> , <b>2018</b> , 27, 321-326	2.5	4
39	Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. <i>Lancet Oncology</i> , <b>2018</b> , 19, 953-964	21.7	134
38	Prospective trial of minimal residual disease assessment by multiparametric flow cytometry for multiple myeloma in the era of bortezomib-based chemotherapy. <i>Bone Marrow Transplantation</i> , <b>2018</b> , 53, 1589-1592	4.4	4
37	Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trials. <i>International Journal of Hematology</i> , <b>2019</b> , 110, 466-473	2.3	8
36	Staging System to Predict the Risk of Relapse in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 633	5.3	11
35	Bortezomib retreatment for relapsed and refractory multiple myeloma in real-world clinical practice. <i>Health Science Reports</i> , <b>2019</b> , 2, e104	2.2	6
34	Response to First Cycle Is the Major Predictor of Long-Term Response to Lenalidomide and Dexamethasone Therapy in Relapsed and Refractory Multiple Myeloma: Can We Spare Patients the Toxicity and Costs of Additional Agents?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2019</b> , 19, 585-592.e1	2	0

33	Understanding mortality in multiple myeloma: Findings of a European retrospective chart review. <i>European Journal of Haematology</i> , <b>2019</b> , 103, 107-115	3.8	12
32	The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma. <i>Leukemia</i> , <b>2019</b> , 33, 2924-2933	10.7	23
31	Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2019</b> , 19, 372-380	2	48
30	Introductory Chapter: Multiple Myeloma in the Era of Novel Therapeutics. <b>2019</b> ,		1
29	Navigating the treatment landscape in multiple myeloma: which combinations to use and when?. <i>Annals of Hematology</i> , <b>2019</b> , 98, 1-18	3	40
28	Validation and cost-effectiveness of an in-house dithiothreitol (DTT) treatment protocol for daratumumab patients in a large tertiary care hospital provides gateway for implementation in smaller community hospitals. <i>Transfusion and Apheresis Science</i> , <b>2019</b> , 58, 152-155	2.4	5
27	Impact of oral oncolytic initiation on medication adherence for pre-existing comorbid chronic conditions. <i>Journal of Oncology Pharmacy Practice</i> , <b>2020</b> , 26, 835-845	1.7	0
26	Pomalidomide desensitization for hypersensitivity: A case report. <i>Journal of Oncology Pharmacy Practice</i> , <b>2020</b> , 26, 1244-1247	1.7	
25	Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment. <i>Leukemia</i> , <b>2020</b> , 34, 3286-3297	10.7	33
24	Safety and efficacy of chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma with renal impairment. <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 2215-2218	4.4	4
23	c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma. <i>European Journal of Haematology</i> , <b>2020</b> , 105, 35-46	3.8	4
22	Checkpoint Inhibitors and Engineered Cells: New Weapons for Natural Killer Cell Arsenal Against Hematological Malignancies. <i>Cells</i> , <b>2020</b> , 9,	7.9	4
21	Outcomes of Daratumumab, Pomalidomide, and Dexamethasone, Followed by High-dose Chemotherapy and Autologous Stem Cell Transplantation, in Patients With Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2021</b> , 21, e212-e219	2	1
20	Efficacy and safety of weekly carfilzomib (70 mg/m), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 358-367	1.9	7
19	Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse. <i>Leukemia</i> , <b>2021</b> , 35, 1722-1731	10.7	18
18	Latest Developments in Cellular Therapy for Multiple Myeloma. <i>Oncology &amp; Hematology Review</i> , <b>2021</b> , 16, 111	0.1	0
17	Management of patients with difficult-to-treat multiple myeloma. <i>Future Oncology</i> , <b>2021</b> , 17, 2089-2105	3.6	0
16	KD-PACE Salvage Therapy for Aggressive Relapsed Refractory Multiple Myeloma, Plasma Cell Leukemia and Extramedullary Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2021</b> , 21, 526-535	2	1

15	A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2021</b> , 21, 775-784	2	2
14	Management of daratumumab interference in Portuguese blood transfusion medicine: A literature review about unmet needs and challenges. <i>International Journal of Blood Transfusion and Immunohematology</i> , <b>2018</b> , 7, 1	0.1	
13	Analyzing Survival Rate of Leukemia Patients Applying Long Term Exponential Model. <i>Asian Pacific Journal of Cancer Prevention</i> , <b>2020</b> , 21, 1539-1543	1.7	
12	Cancer-testis antigen MAGE-C1/ CT7 in multiple myeloma: literature review. <i>Oncogematologiya</i> , <b>2020</b> , 15, 29-37	0.3	
11	Overcoming Proteasome Inhibitor-Refractory Multiple Myeloma With Elotuzumab, Bortezomib, Nelfinavir, and Dexamethasone. <i>World Journal of Oncology</i> , <b>2020</b> , 11, 33-36	16.7	1
10	Estimating the Financial Impact of Gene Therapy*.		2
9	Effects of comprehensive care in patients with multiple myeloma with cardiac dysfunction. <i>American Journal of Translational Research (discontinued)</i> , <b>2021</b> , 13, 4844-4851	3	
8	Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2022</b> ,	2	
7	Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma.. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2022</b> ,	2	0
6	Patient perspectives on symptoms, health-related quality of life, and treatment experience associated with relapsed/refractory multiple myeloma.. <i>Supportive Care in Cancer</i> , <b>2022</b> , 1	3.9	0
5	Data_Sheet_1.PDF. <b>2019</b> ,		
4	Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial.		3
3	A decade of approved first-in-class small molecule orphan drugs: Achievements, challenges and perspectives. <b>2022</b> , 243, 114742		0
2	The Burden of a Multiple Myeloma Diagnosis on Patients and Caregivers in the First Year: Western European Findings. Volume 14, 731-753		0
1	Reply to S. Al Hadidi et al.		0